Ballicules.com

Aripiprazole monohydrate LAI

ABILIFY MAINTENA

What it isLong-acting dopamine partial agonist with serotonin-receptor activity; schizophrenia and maintenance of bipolar I disorder.

Why this oneUnlike aripiprazole lauroxil, it also carries a bipolar I maintenance indication.

What limits itInitiation needs two weeks of overlapping oral aripiprazole (or the two-injection start), and akathisia remains the characteristic complaint.

FDA label

BOXED WARNING Increased mortality in elderly patients with dementia-related psychosis treated with antipsychotics; not approved for dementia-related psychosis.
FDA dosingPopulationStartTargetMax
SchizophreniaAdultsSee initiation (1-day or 14-day)400 mg IM monthly
Bipolar I disorder (maintenance monotherapy)AdultsSee initiation (1-day or 14-day)400 mg IM monthly

Renal Undefined

Hepatic Undefined

400 mg monthly, no sooner than 26 days after the previous injection

Instructions

Cautions

Adverse reactions

Pregnancy Third-trimester exposure: risk of neonatal extrapyramidal/withdrawal symptoms; may decrease milk supply. Registry available.

Lactation Present in human breast milk; may cause clinically relevant decreases in milk supply; monitor infant for dehydration and poor weight gain.

⚠ BOXED WARNING

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Active metabolites

Mechanism of action: Aripiprazole monohydrate LAI ballicule

Aripiprazole monohydrate LAI ballicule: receptor binding, kinetics and half-life diagram

Open Aripiprazole monohydrate LAI in the interactive console ↗

Memory aids: mascots and interaction avatars

Aripiprazole monohydrate LAI ABILIFY MAINTENA mascot mnemonic cartoon
“Man-tenna”

Open Aripiprazole monohydrate LAI in the interactive console ↗